Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / Articles / November / The Shift to Agile, Modular Manufacturing
Cell & Gene Biopharma Facilities & Equipment Bioprocessing Sponsored

The Shift to Agile, Modular Manufacturing

As industry conversations around manufacturing change, we caught up with Cytiva’s Joe Wakowiecki to discuss modular and flexible solutions.

11/28/2025 0 min read Video

Sponsored By

Cytiva

Share

Take a look at the KUBio box trailer with Cytiva’s FlexFactory manufacturing solution that was on display at CPHI Frankfurt 2025!

“The shift towards personalized and advanced therapies, such as MRNA, viral vectors, and cell and gene therapies, has really redefined biomanufacturing, moving away from centralized large-scale facilities towards more agile, more modular environments,” says Joe Wakowiecki, Enterprise Solutions Director of Product Management & Engineering at Cytiva.

Learn more about flexible manufacturing and Cytiva’s end-to-end offering in this video interview with Wakowiecki.

He adds: “Cytiva delivers comprehensive support across the entire biomanufacturing lifecycle, from facility design and process development to equipment integration, automation, operator training and ongoing service. This holistic approach allows customers to focus on science; focus on their product pipeline and operations while Cytiva manages the infrastructure and complexity required to efficiently and compliantly bring manufacturing capacity online.”

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Don’t Forget CDx Developers
Cell & Gene
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Cell & Gene Bioprocessing Biopharma
The Next Decade of Cell and Gene Therapies

April 2, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Regulation & Standards Business & Trends Cell & Gene
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business & Trends Regulation & Standards Cell & Gene
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.